Introduction to adni and study design

Related Terms:

MCI: mild cognitive impairment

Emci: Early cognitive impairment

MCI: mild cognitive impairment

Lmci: Late cognitive impairment

CN: normal volunteers

MHD: Doppler Tissue Imaging, Doppler Tissue Imaging, is a new method to describe the brain structure and a special form of MRI.

 

I. Know adni

1. adni is mainly used for early detection and tracking of Alzheimer's disease. It also provides a platform for global personnel to share data.

2. adni's overall objectives:

(1) detect ad at the earliest possible stage (before dementia) and determine methods for tracking disease progression with biological markers.

(2) apply new diagnostic methods (interventions may be the most effective) at the earliest possible stage ).

(3) validate the biological markers used in the clinical trial of Alzheimer's disease.

 

Ii. Study Design

1. Understanding ad

(1) Alzheimer's disease (AD) is an irreversible neuro-regressive disease that causes mental function loss caused by deterioration of the brain and has not found any preventive or therapeutic methods. It is prone to elderly people over 65 years of age.

2. The study supported the development and research of treatment plans for slowing down and stopping the deteriorating processes of AD. The final goal is to confirm the biological indicators (biological markers) used in the clinical treatment of Alzheimer's disease ). Knowledge gained by studying data from various forms of adni profile and vertical data:

(1) the pathology of ad has appeared when people have a normal appearance and no memory loss, and these people with normal cognition may already have a slight brain atrophy.

(2) There is a typical pattern of starch-like protein deposition, impaired glucose metabolism, and brain structure change in AD.

(3) The decline in cognitive ability is more closely related to Tau, followed by? Deposition.

(4) ad is characterized by the gradual destruction of the brain connection body. With the development of disease, there is less and less connection between important areas of the brain.

(5) Apart from apoE4, many genes are the basis of AD. Adni data has helped identify or confirm 10 of the approximately 20 genes that have been identified.

(6) cerebrovascular diseases can accelerate the development of AD.

(7) The normal cognitive group and the MCI group are both heterogeneous in pathology. Some people do not show signs of AD, some show signs of rapid development of AD, and some show signs of moving towards dementia rather than ad.

3. biomarkers)

(1) biological markers: Biochemical Indicators that can mark changes or possible changes in the structure or function of systems, organs, tissues, cells and subcells, biomarkers may exist before the appearance of clinical symptoms. Therefore, adni uses various biological markers to help predict the onset of Alzheimer's disease.

(2) There are currently five biological markers used for detection: Aβ, Tau-mediated Neuronal Injury and dysfunction, brain structure, memory, and clinical functions. The last two are classic indicators for the diagnosis of dementia, according to the website curve, the effect of Aβ is the most obvious.

4. Research objectives of each stage

Adni participants span four stages: adni 1/go/2/3 and are currently in the adni3 stage. In addition, new volunteers will join the survey at each stage.

(1) adni 1:

• Develop improved methods to develop unified standards for obtaining longitudinal, multi-site MRI and PET data for Alzheimer's disease (AD), mild cognitive impairment (MCI), and elderly control patients
• Obtain generally accessible data warehouses, describe longitudinal changes in brain structure and metabolism, and clinical/cognitive and biological marker data to verify imaging substitutes
• In trials involving these patients, develop methods to determine the maximum Therapeutic Effect
• Test A series of hypotheses based on clinical and biological tag data

(2) adni go:

• Define and describe the ad spectrum phase prior to MCI by recruiting 200 patients with the most mild AD symptoms (emci)
• F18 starch-like protein imaging was performed on CN and lmci subjects of adni1 and newly enrolled emci subjects. Fdpet will be associated with F18 starch-like protein Imaging
• Establish a national F18 starch-like protein Imaging Network, hypothesis for testing the prevalence and severity of brain starch-like Protein Accumulation and Its Relationship with changes in clinical status, MRI, fd-pet, CSF, and adni1 plasma markers
• 3 t mri of all newly enrolled subjects was collected at baseline, 3rd months, 6th months and 12th months
• Longitudinal clinical/cognitive and 500 t mri studies were performed on approximately 1.5 lmci and normal cognitive subjects from adni1 for 2 years
• Collection and analysis of blood and cerebrospinal fluid markers for all newly enrolled emci and follow-up subjects
• Blood samples were collected for DNA and RNA extraction. The newly enrolled subjects will also collect cell-finalized and apocode-type samples

(3) adni 2:

• With the development of pathology, the relationship between clinical, imaging, genetic, and biochemical markers of Alzheimer's disease (AD) is determined.
• Provides information for the neuroscience of AD, identifies diagnostic and prognosis markers and outcome measurements that can be used in clinical trials, and helps develop the most effective clinical trial protocol
• Develop unified standards to obtain longitudinal multi-site MRI and PET data for AD, MCI, and elderly control patients
• Longitudinal clinical, cognitive, MRI, PET (18f-florbetapir and GAF) and blood and cerebrospinal fluid markers were studied for 550 newly enrolled subjects, about 700 subjects of adni1 and adni continued the study for five years.
• Blood samples were collected for DNA and RNA extraction. The newly enrolled subjects will also collect cell-finalized and apocode-type samples
• Verification of clinical diagnostics, imaging, and biological marker substitutes by participation in Neuropathological examinations of adni1, adni go, And adn22.

(4) adni 3:

• Longitudinal changes in cognition and Related Biological Markers
• Prediction of cognitive decline
• Validate the baseline and longitudinal acquisition of biometric markers by associating the results with standard clinical measurements and pathology
• Determine optimal outcome measures for attention to cognitive decline and AV-1451 PET (Tau PET), predictive factors for cognitive decline, normal cognitive participants (level 2 pre-clinical ad trials) inclusion/exclusion criteria for clinical trials of patients with early dementia caused by AD and those with AD (precursor symptom ad test)
• Identifies other known disease proteins found in the AD brain and genes, as well as the role of newly discovered genes, proteins, and analytics, which provide useful information on ad onset/diagnosis

Introduction to adni and study design